However, given that immunotherapy is not a standard treatment option for rectal cancer patients (with the only exception of those with metastatic dMMR/MSI-H tumours, for whom PD-L1 is not a predictive factor anyway), the evidence-building process regarding the frequency, dynamics, and predictive/prognostic value of this biomarker in this disease has lagged behind [55]. This evidence concerns the gene CD274 and neoplasm.